These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32813212)

  • 1. Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia.
    Esposito D; Bobbio E; Di Fraia R; Mone P; Accardo G; De Bellis A; Iorio S; Esposito K; Marfella R; Johannsson G; Ragnarsson O; Pasquali D
    Endocrine; 2020 Nov; 70(2):412-420. PubMed ID: 32813212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the therapy shift from cortisone acetate to modified-release hydrocortisone in a group of patients with adrenal insufficiency.
    Frigerio S; Carosi G; Ferrante E; Sala E; Polledri E; Fustinoni S; Ambrosi B; Chiodini I; Mantovani G; Morelli V; Arosio M
    Front Endocrinol (Lausanne); 2023; 14():1093838. PubMed ID: 36761196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study.
    Dineen R; Martin-Grace J; Ahmed KMS; Frizelle I; Gunness A; Garrahy A; Hannon AM; O'Reilly MW; Smith D; McDermott J; Healy ML; Agha A; Pazderska A; Gibney J; Thompson CJ; Behan LA; Sherlock M
    Eur J Endocrinol; 2021 Feb; 184(2):253-265. PubMed ID: 33513125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study.
    Puglisi S; Rossini A; Tabaro I; Cannavò S; Ferrau' F; Ragonese M; Borretta G; Pellegrino M; Dughera F; Parisi A; Latina A; Pia A; Terzolo M; Reimondo G
    J Endocrinol Invest; 2021 Apr; 44(4):865-872. PubMed ID: 32779106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional steroids vs. dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in adrenal insufficiency: a 10-year study.
    Guarnotta V; Di Stefano C; Tomasello L; Maniscalco L; Pizzolanti G; Arnaldi G; Giordano C
    Eur J Endocrinol; 2024 Aug; 191(3):300-311. PubMed ID: 39171906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.
    Johannsson G; Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Biller BM; Monson JP; Stewart PM; Lennernäs H; Skrtic S
    J Clin Endocrinol Metab; 2012 Feb; 97(2):473-81. PubMed ID: 22112807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency.
    Quinkler M; Miodini Nilsen R; Zopf K; Ventz M; Øksnes M
    Eur J Endocrinol; 2015 May; 172(5):619-26. PubMed ID: 25656494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency.
    Rousseau E; Joubert M; Trzepla G; Parienti JJ; Freret T; Vanthygem MC; Desailloud R; Lefebvre H; Coquerel A; Reznik Y;
    PLoS One; 2015; 10(8):e0135975. PubMed ID: 26317782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency.
    Bannon CAM; Border D; Hanson P; Hattersley J; Weickert MO; Grossman A; Randeva HS; Barber TM
    Front Endocrinol (Lausanne); 2021; 12():641247. PubMed ID: 33776936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.
    Isidori AM; Venneri MA; Graziadio C; Simeoli C; Fiore D; Hasenmajer V; Sbardella E; Gianfrilli D; Pozza C; Pasqualetti P; Morrone S; Santoni A; Naro F; Colao A; Pivonello R; Lenzi A
    Lancet Diabetes Endocrinol; 2018 Mar; 6(3):173-185. PubMed ID: 29229498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal Insufficiency and Response to Stress Dose Hydrocortisone in Patients With Cirrhosis and Vasopressor Dependency Using Cirrhosis-Specific Cortisol Thresholds.
    Vu T; Vallabh M; Laine G
    Ann Pharmacother; 2020 Aug; 54(8):742-749. PubMed ID: 31928081
    [No Abstract]   [Full Text] [Related]  

  • 12. Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone.
    Pilli T; Cardinale S; Cantara S; Dalmazio G; Forleo R; Capezzone M; Bassi C; Negrini M; Ferracin M; Castagna MG
    Endocrine; 2021 Jul; 73(1):177-185. PubMed ID: 33417142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and meta-analysis of the metabolic effects of modified-release hydrocortisone versus standard glucocorticoid replacement therapy in adults with adrenal insufficiency.
    Bannon CA; Gallacher D; Hanson P; Randeva HS; Weickert MO; Barber TM
    Clin Endocrinol (Oxf); 2020 Dec; 93(6):637-651. PubMed ID: 32621327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism.
    Dunne FP; Elliot P; Gammage MD; Stallard T; Ryan T; Sheppard MC; Stewart PM
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):623-9. PubMed ID: 8548948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients.
    Delle Cese F; Corsello A; Cintoni M; Locantore P; Pontecorvi A; Corsello SM; Paragliola RM
    Front Endocrinol (Lausanne); 2020; 11():610904. PubMed ID: 33597926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency.
    Bleicken B; Hahner S; Loeffler M; Ventz M; Decker O; Allolio B; Quinkler M
    Clin Endocrinol (Oxf); 2010 Mar; 72(3):297-304. PubMed ID: 19508599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis.
    Guarnotta V; Ciresi A; Pillitteri G; Giordano C
    Clin Endocrinol (Oxf); 2018 May; 88(5):665-672. PubMed ID: 29368442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency.
    Nilsson AG; Marelli C; Fitts D; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Lennernäs H; Skrtic S; Johannsson G
    Eur J Endocrinol; 2014 Sep; 171(3):369-77. PubMed ID: 24944332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Cardiovascular Risk in Patients with Adrenal Insufficiency: A Short Review.
    Rahvar AH; Haas CS; Danneberg S; Harbeck B
    Biomed Res Int; 2017; 2017():3691913. PubMed ID: 29376070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency.
    Ekstrand E; Esposito D; Ragnarsson O; Isgaard J; Johannsson G
    J Endocr Soc; 2020 Dec; 4(12):bvaa160. PubMed ID: 33241171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.